Molecular Partners AG (XSWX:MOLN) EV-to-EBIT : 1.24 (As of May. 13, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Molecular Partners AG's Enterprise Value is CHF-76.91 Mil. Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-61.95 Mil. Therefore, Molecular Partners AG's EV-to-EBIT for today is 1.24.

The historical rank and industry rank for Molecular Partners AG's EV-to-EBIT or its related term are showing as below:

XSWX:MOLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.39 Med: -0.55 Max: 3.34
Current: 1.24

During the past 11 years, the highest EV-to-EBIT of Molecular Partners AG was 3.34. The lowest was -36.39. And the median was -0.55.

XSWX:MOLN's EV-to-EBIT is ranked better than
63.53% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs XSWX:MOLN: 1.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Molecular Partners AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF-70.22 Mil. Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-61.95 Mil. Molecular Partners AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 88.22%.

Molecular Partners AG EV-to-EBIT Historical Data

The historical data trend for Molecular Partners AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG EV-to-EBIT Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-7.90

-7.02

-7.10

-0.19

1.13

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-0.19	1.03	0.59	1.28	1.13

Competitive Comparison of Molecular Partners AG's EV-to-EBIT

For the Biotechnology subindustry, Molecular Partners AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's EV-to-EBIT falls into.

Molecular Partners AG EV-to-EBIT Calculation

Molecular Partners AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-76.906	/	-61.95
	=	1.24

Molecular Partners AG's current Enterprise Value is CHF-76.91 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-61.95 Mil.

Molecular Partners AG (XSWX:MOLN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Molecular Partners AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-61.95	/	-70.218208
	=	88.22 %

Molecular Partners AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF-70.22 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-61.95 Mil.

Molecular Partners AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.